Comparative Pharmacology
Head-to-head clinical analysis: EMBLAVEO versus HEDULIN.
Peer-Reviewed Evidence
Head-to-head clinical analysis: EMBLAVEO versus HEDULIN.
EMBLAVEO vs HEDULIN
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
EMBLAVEO is a combination of a beta-lactam antibiotic (cefepime) and a beta-lactamase inhibitor (enmetazobactam). Enmetazobactam inhibits a broad range of beta-lactamases, including ESBLs and AmpC, thereby protecting cefepime from hydrolysis and extending its spectrum of activity against beta-lactamase-producing Gram-negative bacteria.
HEDULIN (phenindione) is an anticoagulant that inhibits vitamin K-dependent synthesis of coagulation factors II, VII, IX, and X in the liver, thereby reducing thrombus formation.
EMBLAVEO (imipenem/cilastatin/relebactam) is administered intravenously. The recommended adult dose is 1.25 g (imipenem 500 mg, cilastatin 500 mg, relebactam 250 mg) every 6 hours infused over 30 minutes.
Oral, 200-400 mg initially, then 100-200 mg every 6-12 hours; maximum daily dose 1200 mg.
None Documented
None Documented
Terminal elimination half-life is 11–12 hours in healthy adults; prolonged to 20–30 hours in severe renal impairment (CrCl <30 mL/min).
Terminal elimination half-life is 18-24 hours in patients with normal renal function; may be prolonged to 30-40 hours in renal impairment, necessitating dose adjustment.
Renal excretion of unchanged drug accounts for approximately 30% of the dose; biliary/fecal elimination accounts for about 70% (60% fecal as parent drug and metabolites, 10% biliary).
Renal excretion of unchanged drug accounts for approximately 70% of elimination; the remainder is metabolized hepatically and excreted in feces via bile.
Category C
Category C
Anticoagulant
Anticoagulant